torcetrapib

(redirected from CETP Inhibitors)

torcetrapib

A cholesterol ester transfer protein (CETP) inhibitor drug that has been shown capable of substantially increasing levels of high density lipoprotein (HDL) cholesterol. A major trial of this drug in conjunction with atorvastatin was stopped by Pfizer at the end of 2006.
References in periodicals archive ?
He added: These findings are in marked contrast to the disappointing results of previous trials of other CETP inhibitors which were stopped after about two years due to unexpected hazards or an apparent lack of efficacy.
CETP inhibitors act to increase HDL-C concentrations by preventing the CETP-catalyzed exchange of TGs in apoB-containing lipoproteins for HDL cholesteryl esters.
Niacin, fibrates and investigational drugs called CETP inhibitors have been tested in clinical trials to determine if the HDL-raising properties of these drugs would further reduce cardiac events.
In past reports, the only other CETP inhibitors to complete phase III trials either showed no incremental benefit like evacetrapib, which happened with dalcetrapib (N Engl J Med.
The decision is also the latest disappointment for this class of drags, known as CETP inhibitors, which can raise the levels of so-called good cholesterol while lowering the levels of bad cholesterol.
But pivotal phase III trials of two other CETP inhibitors are well underway: anacetrapib, which is the focus of the 30,000-patient REVEAL trial; and evacetrapib, featured in the 11,000-patient ACCELERATE trial.
Current status of CETP inhibitors in the treatment of hyperlipidemia: an update.
These findings point the way to the design of safer, more effective next generation CETP inhibitors that could help prevent the development of heart disease.
Medicines called CETP inhibitors that mimic the effect of the gene variation in the study are under development by Merck & Co.
Growth will be driven by the launches of Eli Lilly/Daiichi Sankyo's Efient/Effient, AstraZeneca's Brilinta and Schering-Plough's SCH-530348 as well as the introduction of two new CETP inhibitors from Roche/Japan Tobacco and Merck.
The question facing researchers, he said, is whether the mortality risk associated with torcetrapib will extend to any of the other CETP inhibitors under development by Hoffmann--La Roche Inc.
Specific LXR agonists, synthetic HDLs, HDL function boosting agents (D4F), CETP inhibitors, and novel PPAR agonists are in clinical trials.